连续性血液净化治疗患儿静脉留置导管感染风险预测体系的构建及应用

目的:探讨连续性血液净化治疗患儿静脉留置导管感染风险因素,据此构建风险预测体系,并检验其实际应用效果,以期为临床预防护理提供依据。方法:选取医院2018年4月—2020年4月收治的400例连续性血液净化治疗患儿,按两组基础资料具有匹配性原则将其分为构建组300例、验证组100例,统计构建组中静脉留置导管感染患儿例数,通过单因素分析、多因素Logistic回归分析筛选静脉留置导管感染的独立危险因素,据此构建风险预测体系,并检验其在验证组中的应用效果。结果:经统计得到,构建组中静脉留置导管感染患儿共66例,感染发生率为22.00%;单因素分析得到,连续性血液净化治疗患儿静脉留置导管感染风险因素有穿刺部位、导管留置时间、插管次数、血流速度、血红蛋白、遵医依从性、抗生素使用时间、操作人员手卫生(P<0.05);多因素Logistic回归分析得到,连续性血液净化治疗患儿静脉留置导管感染独立风险因素有股静脉置管、导管留置时间>7 d、血流速度>180 mL/min、血红蛋白<100 g/L、遵医依从性差、抗生素使用时间>7 d(P<0.05);构建得到连续性血液净化治疗患儿静脉留置导管感染风险预测体系为P=1/[1+e^(-(-1.935+1.635×股静脉置管+1.740×导管留置时间>7 d+1.725×血流速度>180 mL/min+2.241×血红蛋白<100 g/L+2.089×遵医依从性差+1.331×抗生素使用时间>7 d))],ROC曲线分析显示,曲线下面积AUC=0.881,灵敏度为86.67%,特异性为97.14%,准确率为94.00%。结论:连续性血液净化治疗患儿静脉留置导管感染风险大,且风险因素复杂,研究构建的静脉留置导管感染风险预测体系灵敏度高、特异性强,评估准确率高。     

中药肠道灌洗联合血液净化治疗急性农药中毒的临床疗效探讨

目的 探讨中药肠道灌洗联合血液净化治疗急性农药中毒的临床疗效。方法 选取2014年4月～2019年10月本院收治的50例急性农药中毒患者为研究对象,并根据不同的治疗方案将患者分为对照组与观察组,各25例,对照组采用常规治疗联合血液净化治疗,而观察组在对照组的基础上采用中药肠道灌洗治疗,比较两组患者的临床疗效及血压、血气指标情况。结果 治疗后,观察组的临床总有效率为96.00%,对照组为76.00%,两组比较,观察组明显高于对照组;同时观察组的收缩压(SBP)、舒张压(DBP)与酸碱度(pH)高于对照组,动脉血氧分压(PaO2)与动脉血二氧化碳分压(PaCO2)低于对照组,组间比较差异有统计学意义(P0.05)。结论 对急性农药中毒患者实施中药肠道灌洗联合血液净化治疗,能有效改善患者的血压、血气指标,具有显著的临床疗效。     

同时分离纯化枇杷叶中熊果酸和科罗索酸工艺研究

目的采用大孔吸附树脂吸附法同时分离纯化枇杷叶中的熊果酸和科罗索酸,并确定分离纯化工艺。方法采用乙醇浸提法将枇杷叶中的熊果酸和科罗索酸进行提取分离纯化,对15种大孔吸附树脂进行筛选,利用大孔吸附树脂柱层析同时分离纯化枇杷叶中的熊果酸和科罗索酸。结果经过对15种大孔吸附树脂的筛选,HPD722的吸附量最好,因此选择HPD722大孔吸附树脂进行柱分离,并确立了最佳的分离纯化工艺。结论HPD722大孔吸附树脂能够使熊果酸和科罗索酸达到较好的分离纯化,工艺可行。     

Pathological classification and prognosis of renal damage caused by antineutrophil cytoplasmic antibody associated vasculitis

Objective To analyze the pathological characteristics and prognostic factors of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods A retrospective analysis of AAV patients with renal biopsy results admitted to Kidney Disease Center of the First Affiliated Hospital from January 2004 to February 2017 was performed. The patients were divided into 4 types according to Berden classification, and their clinical, pathological characteristics and prognosis were compared. The survival curves of each type of patients were plotted by Kaplan-Meier method, and the difference of survival curves was compared using Log-rank test. With entering the maintenance dialysis as the endpoint, Cox regression was used to analyze the prognostic factors. Results A total of 175 patients with AAV, including 59 cases (33.7%) of focal type, 39 cases (22.3%) of crescent type, 32 cases (18.3%) of sclerosis type, 45 cases (25.7%) of mixed type. The basal serum creatinine levels in crescent type group and sclerosis type group were significantly higher than those in the focal type group or mixed type group (all P＜0.05), and loop necrosis rate in sclerosis type group was significantly lower than chat in the focal type group or crescent type group (both P＜0.05). The median follow-up period was 11.8 (0.5-86.7) months. The event-free survival rates were 83.1%, 77.8%, 64.1% and 50.0% in the focal type, mixed type, crescent type and sclerotic type groups (Log-rank χ2=11.537, P=0.009). Cox regression analysis showed higher parathyroid hormone (HR=1.013, 95%CI 1.007-1.019, P＜0.001), glomerular sclerosis ≥50% (HR=10.532, 95%CI 2.903-38.203, P＜0.001) were independent risk factors for AAV patients entering maintenance dialysis, and higher estimated glomerular filtration rate (HR=0.943, 95%CI 0.896-0.993, P=0.025) was protective factor. Conclusion The prognosis of AAV renal damage is worsened according to focal, mixed, crescent and sclerosis types. Lower estimated glomerular filtration rate, higher parathyroid hormone and glomerular sclerosis ≥50% are independent risk factors for AAV patients entering maintenance dialysis.     

疱疹病毒治疗性疫苗研究进展

疱疹病毒感染极为普遍,可表现为原发性、潜伏性或复发性感染,几乎能在所有的动物中建立潜伏感染,且潜伏感染期间病毒保持休眠状态,宿主不表现出任何临床症状,机体在受到一些应激后,潜伏的病毒被重新激活,使机体引起复发性感染。目前预防性疫苗免疫接种仍是预防疱疹病毒感染和控制其相应疾病流行的有效手段,然而免疫接种后机体免疫系统虽能够控制感染,但却未能防止机体发生复发性感染并不能提供全面的保护。治疗性疫苗能清除潜伏感染或阻止复发性感染,可以有效地控制此类疾病的复发。因此,接种治疗性疫苗是未来防控和净化疱疹病毒的一种可行策略。本文针对在研的疱疹病毒HSV、EBV治疗性疫苗的研究进展进行综述,旨在为其余疱疹病毒治疗性疫苗的研发拓展思路。     

血液净化技术在危重患者治疗中的应用进展

近年来血液净化技术不断发展，新模式和新材料不断涌现。在多种病因导致的危重患者中，血液净化均可以发挥重要的治疗作用。特别是对于内环境严重紊乱的危重患者，血液净化已经成为重要的生命支持手段。因为连续性血液净化技术对血流动力学影响较小，在危重患者的治疗中更具有优势。免疫吸附等新技术的出现，对一些危重患者的原发病也有很好的治疗效果。但是目前还存在抗凝剂选择、容量控制等需要进一步研究的问题。     

Expert recommendations on blood purification treatment protocol for patients with severe COVID-19

Coronavirus disease (COVID-19) was first diagnosed in Wuhan in December 2019. The World Health Organization defined the subsequent outbreak of COVID-19 worldwide as a public health emergency of international concern. Epidemiological data indicate that at least 20% of COVID-19 patients have severe disease. In addition to impairment of the respiratory system, acute kidney injury (AKI) is a major complication. Immune damage mediated by cytokine storms and concomitant AKI is a key factor for poor prognosis. Based on previous experience of blood purification for patients with severe acute respiratory syndrome and Middle East respiratory syndrome combined with clinical front-line practice, we developed a blood purification protocol for patients with severe COVID-19. This protocol is divided into four major steps. The first step is to assess whether patients with severe COVID-19 require blood purification. The second step is to prescribe a blood purification treatment for patients with COVID-19. The third step is to monitor and adjust parameters of blood purification. The fourth step is to evaluate the timing of discontinuation of blood purification. It is expected that blood purification will play a key role in effectively reducing the mortality of patients with severe COVID-19 through the standardized implementation of the present protocol.     

Extracorporeal blood purification treatment options for COVID-19: The role of immunoadsorption

The activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19.     

血液净化中心设备管理研究进展

血液净化中心是医院血液透析患者开展血液净化治疗的主要场所。在血液净化中心开展血液净化治疗的患者通常来说免疫功能低下,容易发生感染,并且对设备具有较强的依赖性。因此血液净化中心设备管理质量直接影响着血液透析中心的血液净化治疗效果。这便要求血液净化中心应该不断加强设备管理,提高设备管理质量,为患者的治疗提供更好的服务。因此近些年人们对于血液净化中心设备管理的重视程度不断提高,很多专家关于血液净化中心的设备管理开展了很多研究工作,本文将近些年的研究进展进行综述,以期为血液净化中心的设备管理提供借鉴。     

Assessment of extravascular lung water by measuring the number of pulmonary ultrasound B-lines before and after CBP in patients with MODS

To determine whether the change in the number of pulmonary ultrasound B-line can accurately assess the extravascular lung water (EVLW) before and after continuous bedside blood purification (CBP) in patients with multiple organ dysfunction syndrome (MODS).Seventy-six patients with MODS who underwent CBP were examined within 24 hours before and after CBP using pulmonary ultrasound to detect the number of ultrasound B-line or using pulse indicator continuous cardiac output method to examine extravascular lung water, blood oxygenation index, and B-type natriuretic peptide (BNP) content. The correlation of the change in the number of B lines before and after CBP treatment with the negative balance of 24 hours liquid, the change of oxygenation index, and BNP content were analyzed.In the 76 patients, CBP treatment significantly decreased EVLW, the number of B-line, and BNP (P < .05 for all), while it significantly increased the oxygenation index (P < .05). Correlation analysis showed that the decrease in B-line number after CBP treatment was positively correlated with the 24 hours negative lung fluid balance, decrease of EVLW, oxygenation index improvement, and decreased BNP content. The change in the numbers of pulmonary ultrasound B-line can accurately assess the change of EVLW before and after CBP treatment and reflect the efficiency of ventilation in the lungs and the risk of heart failure.Thus, it can replace pulse indicator continuous cardiac output as an indicator for evaluating EVLW in patients with MODS treated with CBP.